Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for nonalcoholic fatty liver disease
IRCT20240326061366N1Phase 3Completed
- Sponsor
- Yasouj University of Medical Sciences
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of empagliflozin in metabolic dysfunction-associated steatotic liver disease (MASLD) (2 arms), sponsored by Yasouj University of Medical Sciences. Primary endpoints: Decrease in liver enzymes, Reduction in inflammatory factors and 1 more. Started Aug 2024; status: completed.
02
Drugs
empagliflozin
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on IRCT20240326061366N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240326061366N1.